Last updated on November 2019

Lenalidomide Monotherapy in R/R DLBCL


Brief description of study

This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)

Detailed Study Description

Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.

Clinical Study Identifier: NCT04150328

Find a site near you

Start Over

MorphoSys Research Site

Rochester, MN United States
  Connect »

MorphoSys Research Site

Saint Louis, MO United States
  Connect »

MorphoSys Research Site

Manhasset, NY United States
  Connect »

MorphoSys Research Site

New York, NY United States
  Connect »

MorphoSys Research Site

Dublin, OH United States
  Connect »

MorphoSys Research Site

Charleston, SC United States
  Connect »

MorphoSys Research Site

Greenville, SC United States
  Connect »

MorphoSys Research Site

San Giovanni Rotondo, Italy
  Connect »